Vir Biotechnology

Our CEO Marianne De Backer, joined @carolmassar and @timsteno on @BloombergTV to discuss promising VIR-5500 Phase 1 data in metastatic castration-resistant prostate cancer and our strategic collaboration with Astellas Pharma. Watch the conversation ➡️ bit.ly/3MZwsEj

Our CEO Marianne D. De Backer, MSc, PhD, MBA, will dive into our latest #VirBiotechnology announcements during a fireside chat at the Leerink Partners Global Healthcare Conference on Tues., Mar. 10, at 1:40 p.m. ET/10:40 a.m. PT. Join the webcast here ➡️ bit.ly/4sv2cAp

We were pleased to share positive Phase 1 data of our PSMA-targeting, dual-masked #TCE VIR-5500 at @ASCO #GU26 and engage with the oncology community in attendance. We’re looking forward to advancing dose-expansion cohorts in the second quarter of 2026. ➡️ bit.ly/4rI5VdV

👉 Attending @ASCO  #GU26 Cancers Symposium? Today #VirBiotechnology will present new data from our Phase 1 trial evaluating PSMA-targeting, dual-masked T-cell engager VIR-5500 in advanced #mCRPC in an oral session at 5 p.m. PT. bit.ly/4qU1Q4V #ProstateCancer

📣A meaningful moment for #VirBiotechnology as the iconic @Nasdaq MarketSite Tower in Times Square spotlighted our global strategic collaboration with Astellas Pharma to advance our PSMA-targeting, dual-masked #TCE VIR-5500 for prostate cancer. ➡️ bit.ly/4rDzrkU

#VirBiotechnology News: We announced positive updated Phase 1 data results for our PSMA-targeting, dual-masked #TCE VIR-5500 in participants with metastatic castration-resistant prostate cancer #mCRPC. Learn more in the replay of our conference call ➡️ bit.ly/4tefwtZ

#VirBiotechnology News: We are proud to announce a global strategic collaboration with Astellas Pharma to advance our PSMA-targeting dual-masked T-cell engager #TCE VIR-5500 for the treatment of prostate cancer.➡️ bit.ly/4sbdI3K

👉 #VirBiotechnology will provide a corporate update and report Q4 and full year 2025 financial results. Join our investor conference call on Mon., Feb. 23, at 5:30 p.m. ET / 2:30 p.m. PT. ➡️ bit.ly/4tefwtZ #Earnings

👉 #VirBiotechnology will provide a corporate update and report Q4 and full year 2025 financial results on Mon., Feb. 23, at 5:30 p.m. ET / 2:30 p.m. PT. Join us for our investor conference call at ➡️ bit.ly/4tefwtZ #Earnings

A great spotlight of our positive Phase 2 SOLSTICE data at Week 48 previously published in @NEJM. See updated SOLSTICE study data that includes participants evaluated at 72 and 96 weeks, presented recently @jpmorgan Healthcare Conference here ➡️ bit.ly/4q9lsl3

At #JPM26, we shared new positive Phase 2 SOLSTICE data in #CHD, our progress in building a pipeline of cancer immunotherapies, and our 2026 company milestones. Listen to our full presentation. ➡️ bit.ly/4aZIqHJ #PatientsAreWaiting #HepatitisDelta #Oncology

Today at 3:45 p.m. PT, join us virtually or live at #JPM26. We’ll be presenting key updates on our chronic hepatitis delta and oncology programs including 2026 clinical milestones.➡️ bit.ly/45iDCtp #PatientsAreWaiting #HepatitisDelta #Oncology #Immunotherapy

We are reporting new positive data from the ongoing SOLSTICE Phase 2 trial at #JPM26. Participants on our combination therapy for chronic hepatitis delta (CHD) showed increased viral suppression of HDV RNA versus treatment with monotherapy. Join Jan. 14 ➡️ bit.ly/45iDCtp

#VirBioNews: Today we provided key updates on our chronic hepatitis delta and oncology programs including 2026 clinical milestones. Read more➡️ bit.ly/4sD3v0L #PatientsAreWaiting #Immunotherapy #HepatitisDelta #Oncology

Our CEO Marianne De Backer, MSc, PhD, MBA, will join John Carroll on Jan. 13, at 9:50 a.m. PT. Tune in virtually or live next week at Endpoints @ #JPM26. ➡️ bit.ly/VirBio #PatientsAreWaiting #Immunotherapy #HepatitisDelta #Oncology

Chief Executive Officer Marianne D. De Backer, MSc, PhD, MBA, will present at #JPM26 on Wednesday, Jan. 14 at 3:45 p.m. PT. Join us live or virtually ➡️ bit.ly/45iDCtp #PatientsAreWaiting

📢 Vir Bio Announces Commercial Agreement with Norgine for Chronic #HepatitisDelta Treatment 📢 We look forward to maximizing the potential impact of the combination of tobevibart and elebsiran in Europe, Australia and New Zealand. Read ➡️ ow.ly/quEK50XKAnY

"You cannot just think about treatment, you have to think about prevention and you have to think about cure." Marianne De Backer, M.Sc., Ph.D., M.B.A., CEO and Director, Vir Biotechnology, spoke about AI at the #ForbesHealth Summit. forbes.com/sites/rachelpe…

Join us on Dec. 3 for a fireside chat with our Chief Executive Officer Marianne De Backer, MSc, PhD, MBA, at the 8th Annual Evercore Healthcare Conference. Learn more here ➡️ ow.ly/zW3q50XAg2q #PatientsAreWaiting #Oncology #HepatitisDelta

This World #HepTest Week, as we advance toward our goal to deliver an effective treatment option for people living with #HepatitisDelta - we spotlight how pivotal early detection is for better patient outcomes. #PatientsAreWaiting @Hep_Alliance